U.S. Markets closed

Loblaw Companies Limited (LBLCF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
58.25+0.47 (+0.81%)
At close: 3:42PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close57.78
Open58.20
Bid0.00 x 0
Ask0.00 x 0
Day's Range58.20 - 58.25
52 Week Range43.27 - 58.25
Volume497
Avg. Volume2,585
Market Cap20.147B
Beta (5Y Monthly)-0.09
PE Ratio (TTM)23.37
EPS (TTM)2.49
Earnings DateJul 21, 2021 - Jul 26, 2021
Forward Dividend & Yield1.07 (1.91%)
Ex-Dividend DateMar 12, 2021
1y Target EstN/A
  • Loblaw Companies Limited Announces Election of Directors
    CNW Group

    Loblaw Companies Limited Announces Election of Directors

    Loblaw Companies Limited ("Loblaw") (TSX: L) today announced that all of the nominee directors listed in the management proxy circular dated March 26, 2021, were elected as directors of Loblaw. The vote was conducted at the Company's Annual Meeting of Shareholders, held in a virtual meeting format, on May 6, 2021. The results of the vote are set out below:

  • Shoppers Drug Mart launches rapid COVID-19 screening programs to help employers safely operate and reopen
    CNW Group

    Shoppers Drug Mart launches rapid COVID-19 screening programs to help employers safely operate and reopen

    Shoppers Drug Mart Inc. ("Shoppers Drug Mart") announced today COVID-19 antigen screening options for employers who want a quick and convenient tool to more safely operate or reopen their businesses. Rapid antigen tests can provide results within 15-20 minutes, giving workplaces additional and readily accessible information to help keep their employees safe.

  • Loblaw Posts Better-Than-Expected Results In 1Q
    SmarterAnalyst

    Loblaw Posts Better-Than-Expected Results In 1Q

    Loblaw Companies (L) announced better-than-expected financial results for the quarter ended March 27, driven by an online sales boom. Canada’s largest grocer reported a quarterly profit 30% higher than a year ago, boosted by better numbers in its financial services business. Loblaw Companies’ revenue for 1Q 2021 came in at C$11.87 billion, an increase of 0.6% from the revenue of C$11.80 billion reported in 1Q 2020. The company beat analysts' estimates of C$11.72 billion, according to IBES data from Refinitiv. Food retail (Loblaw) same-store sales increased 0.1%, while drug retail (Shoppers Drug Mart) same-store sales declined 1.7%. Meanwhile, the food and pharmacy company earned a profit available to common shareholders of C$313 million (C$0.90 per diluted share), an increase of 30.4% from C$240 million (C$0.66 per diluted share) in 1Q 2020. Loblaw's financial services sector saw a reduction of C$20 million in its provisions for expected credit losses in the quarter, compared to a C$50 million increase in the first quarter of 2020. On an adjusted basis, the company earned C$1.13 per diluted share, an increase of 16.5% from the adjusted profit of C$0.97 reported in the first quarter of 2020. It exceeds the average analysts' estimate of C$0.87 per share. Loblaw’s Executive Chairman Galen G. Weston said, “A year into the pandemic, our stores, supply chain, and digital assets have demonstrated resilience and innovation and are better prepared than ever to serve the needs of Canadians. Our strong financial results reflect continued momentum and positive consumer response to the value and services in our stores and our expanding online solutions." Loblaw Companies experienced a substantial boost in e-commerce sales in the first quarter, as they grew 133% from the first quarter of 2020. (See Loblaw Companies stock analysis on TipRanks) Last week, BMO Capital analyst Peter Sklar reiterated a Hold rating on the stock and a $57.77 (C$71.00) price target (3.5% upside potential). Sklar said that the growth of online grocery is weighing on margins. Overall, Loblaw Companies scores a Moderate Buy consensus rating among analysts based on 3 Buys and 4 Holds. The average analyst price target of C$76.57 implies an 11.7% upside potential from current levels. Shares have increased by 10% year-to-date. Related News:Brookfield Renewable Beats On Revenue, Misses On Earnings; Shares Drop 3%Bausch Health Misses Estimates In 1Q; Shares Plunge 10%WELL Health Closes ExecHealth Acquisition More recent articles from Smarter Analyst: Sony Invests In Discord, Will Integrate App Into PlayStation Consoles Discovery Signs Long-Term Deal With Hulu - Report Ericsson Partners With Telarus and AT&T To Harness $90B SMB Market Twitter Acquires Scroll and Opens Space To Enhance Communication